Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Bulude Eerdeng holds a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. Currently, there is 1 pending office action assigned to a distinct examiner. This prosecution activity takes place within a distinct art unit, reflecting the technical focus of the application.
The busiest examiner identified is FIEBIG, RUSSELL G, who is handling 1 busiest examiner pending office action. As this figure matches the total number of pending office actions, the examiner is responsible for all active matters in the portfolio. This arrangement provides a consistent examination environment for the company's intellectual property.
In the Biotechnology & Pharmaceuticals sector, the presence of only one distinct examiner simplifies the management of the active workload. The data confirms that no other examiners or art units are currently involved in the prosecution. Practitioners can utilize this centralized structure to maintain a uniform approach across the company's pending filings.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FIEBIG, RUSSELL G | 1 | 62.6% | +25.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18287590 | KUMIS-DERIVED EXOSOME AND USE THEREOF | FIEBIG, RUSSELL G | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18287590 | KUMIS-DERIVED EXOSOME AND USE THEREOF | FIEBIG, RUSSELL G | 1655 | §103 | Final Rejection | — | Pending | Oct 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBulude Eerdeng has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Russell G Fiebig has the most, with 1 of Bulude Eerdeng's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
